FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954544268> ?p ?o ?g. }

• W2954544268 endingPage "330" @default.
• W2954544268 startingPage "330" @default.
• W2954544268 abstract "INTRODUCTION: Oncogenic mutations in EGFR are found in 15-30% of non-small cell lung cancers (NSCLC). Patients with EGFR -mutant NSCLC derive clinical benefit from EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and afatinib. Recently, a 3 rd -generation EGFR TKI, osimertinib, was approved for first-line treatment of metastatic EGFR -mutant NSCLC based on improved progression-free survival compared to earlier EGFR TKIs. Unfortunately, resistance to osimertinib and other EGFR TKIs invariably develops. While secondary mutations in EGFR are a common resistance mechanism, resistance also frequently arises independent of EGFR alterations. We hypothesize that “bypass” signaling pathways are responsible for much of this off-target drug resistance. Moreover, we hypothesize that these bypass signaling pathways are pharmacologically targetable. DESIGN: Osimertinib-resistant cell lines were developed for 6 months and characterized via Western blot, CellTiter Blue, and RNA-seq. Drug screens were conducted with nine matched isogenic osimertinib-sensitive and -resistant cell lines, using continual imaging and cell counting on an automated high-content imaging microscope, in the presence and absence of osimertinib. The drug-induced proliferation (DIP) rate metric was used to generate time-resolved analyses of drug effect while minimizing effect of deviations in plating density. A library of 1176 compounds was selected based on: (1) published bioactivity/safety data; (2) prior clinical investigation; (3) target diversity; (4) minimized chemical redundancy. RESULTS: No de novo secondary EGFR alterations were found in any osimertinib-resistant cell line. Clear evidence of epithelial-to-mesenchymal transition was apparent in 4 of 9 resistant lines, which correlated with decreased EGFR and ErbB-family protein expression. FGFR1 mRNA expression was elevated in 8 of 9 resistant lines, and protein expression increased in 4 of 9 osimertinib-resistant lines. Initial drug screens have identified candidate “hits” which are more efficacious in an osimertinib-resistant cell line than its matched parental line. CONCLUSION: These results suggest that acquired osimertinib resistance, relying on certain “bypass” signaling pathways, arise independently in multiple cell culture models. Secondly, these results suggest that such “bypass”-mediated resistance can be identified and is pharmacologically targetable. Lastly, screening data demonstrates the utility and robustness of the DIP rate metric in image-based high-throughput drug screens. Citation Format: David Westover, Yun-Kai Zhang, Yingjun Yan, Stephen Himmelberg, Darren R. Tyson, Joshua A. Bauer, Christine M. Lovly. High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 330." @default.
• W2954544268 created "2019-07-12" @default.
• W2954544268 creator A5005174983 @default.
• W2954544268 creator A5012459905 @default.
• W2954544268 creator A5061250244 @default.
• W2954544268 creator A5064049869 @default.
• W2954544268 creator A5072643647 @default.
• W2954544268 creator A5074068244 @default.
• W2954544268 creator A5089131845 @default.
• W2954544268 date "2019-07-01" @default.
• W2954544268 modified "2023-09-23" @default.
• W2954544268 title "Abstract 330: High-throughput drug screens in osimertinib-resistant NSCLC cell lines, using continuous high-content imaging, identify potential co-targets to overcome acquired resistance" @default.
• W2954544268 doi "https://doi.org/10.1158/1538-7445.sabcs18-330" @default.
• W2954544268 hasPublicationYear "2019" @default.
• W2954544268 type Work @default.
• W2954544268 sameAs 2954544268 @default.
• W2954544268 citedByCount "0" @default.
• W2954544268 crossrefType "journal-article" @default.
• W2954544268 hasAuthorship W2954544268A5005174983 @default.
• W2954544268 hasAuthorship W2954544268A5012459905 @default.
• W2954544268 hasAuthorship W2954544268A5061250244 @default.
• W2954544268 hasAuthorship W2954544268A5064049869 @default.
• W2954544268 hasAuthorship W2954544268A5072643647 @default.
• W2954544268 hasAuthorship W2954544268A5074068244 @default.
• W2954544268 hasAuthorship W2954544268A5089131845 @default.
• W2954544268 hasConcept C121608353 @default.
• W2954544268 hasConcept C126322002 @default.
• W2954544268 hasConcept C143998085 @default.
• W2954544268 hasConcept C2776256026 @default.
• W2954544268 hasConcept C2777626846 @default.
• W2954544268 hasConcept C2778087573 @default.
• W2954544268 hasConcept C2779438470 @default.
• W2954544268 hasConcept C2780586478 @default.
• W2954544268 hasConcept C502942594 @default.
• W2954544268 hasConcept C54355233 @default.
• W2954544268 hasConcept C71924100 @default.
• W2954544268 hasConcept C81885089 @default.
• W2954544268 hasConcept C86803240 @default.
• W2954544268 hasConceptScore W2954544268C121608353 @default.
• W2954544268 hasConceptScore W2954544268C126322002 @default.
• W2954544268 hasConceptScore W2954544268C143998085 @default.
• W2954544268 hasConceptScore W2954544268C2776256026 @default.
• W2954544268 hasConceptScore W2954544268C2777626846 @default.
• W2954544268 hasConceptScore W2954544268C2778087573 @default.
• W2954544268 hasConceptScore W2954544268C2779438470 @default.
• W2954544268 hasConceptScore W2954544268C2780586478 @default.
• W2954544268 hasConceptScore W2954544268C502942594 @default.
• W2954544268 hasConceptScore W2954544268C54355233 @default.
• W2954544268 hasConceptScore W2954544268C71924100 @default.
• W2954544268 hasConceptScore W2954544268C81885089 @default.
• W2954544268 hasConceptScore W2954544268C86803240 @default.
• W2954544268 hasLocation W29545442681 @default.
• W2954544268 hasOpenAccess W2954544268 @default.
• W2954544268 hasPrimaryLocation W29545442681 @default.
• W2954544268 hasRelatedWork W2026164958 @default.
• W2954544268 hasRelatedWork W2591748786 @default.
• W2954544268 hasRelatedWork W2741198065 @default.
• W2954544268 hasRelatedWork W2741532385 @default.
• W2954544268 hasRelatedWork W2792628494 @default.
• W2954544268 hasRelatedWork W2805550471 @default.
• W2954544268 hasRelatedWork W2885697386 @default.
• W2954544268 hasRelatedWork W2886226874 @default.
• W2954544268 hasRelatedWork W2886233454 @default.
• W2954544268 hasRelatedWork W2895725626 @default.
• W2954544268 hasRelatedWork W2953559990 @default.
• W2954544268 hasRelatedWork W2955339590 @default.
• W2954544268 hasRelatedWork W2972398605 @default.
• W2954544268 hasRelatedWork W3018637389 @default.
• W2954544268 hasRelatedWork W3023726387 @default.
• W2954544268 hasRelatedWork W3130084170 @default.
• W2954544268 hasRelatedWork W3167817260 @default.
• W2954544268 hasRelatedWork W3182406594 @default.
• W2954544268 hasRelatedWork W3185133411 @default.
• W2954544268 hasRelatedWork W3204493825 @default.
• W2954544268 hasVolume "79" @default.
• W2954544268 isParatext "false" @default.
• W2954544268 isRetracted "false" @default.
• W2954544268 magId "2954544268" @default.
• W2954544268 workType "article" @default.